I sat in a cardiologist’s waiting room last October — not as a patient, but as a journalist working on a story about women and heart disease. The TV in the corner was playing a segment about “Ozempic face.” The woman next to me, probably 60, turned and said, “My daughter wants to stop her Ozempic because she read it makes your face look old.” Her daughter had type 2 diabetes and a family history of heart attacks.
I wanted to grab that woman by the shoulders and say: the data now shows semaglutide may be one of the most important cardiovascular drugs since statins, and your daughter is thinking about quitting because of a TikTok trend.
I didn’t say that. I said something gentler. But I went home and started writing this piece, because that conversation has been rattling around in my head for four months.
That’s the cost of the “weight loss drug” framing. It’s not just wrong. It’s actively dangerous. And the data that proves it has been sitting in plain sight since late 2023.
The SELECT Trial Changed Everything. Nobody Noticed.
In November 2023, the SELECT trial reported its primary results: semaglutide reduced major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in patients with established heart disease and overweight or obesity. These were patients without diabetes. The drug wasn’t treating their blood sugar. It was protecting their hearts.
A 20% reduction in MACE is massive. For context, statins reduce MACE by roughly 25-30% in high-risk populations. Semaglutide is operating in the same league as the drug that redefined preventive cardiology.
But SELECT got buried under “Ozempic face” headlines. The most important cardiovascular trial result in a decade was treated as a footnote to a weight loss story.
I’ve been reporting on GLP-1 medications for three years. This is the single most frustrating thing I’ve witnessed in this space. And that’s a competitive category.
The New Data: It’s Not Just Hearts. It’s Everything.
A prespecified exploratory analysis of SELECT, published in JAMA Cardiology in late 2025, asked a broader question: does semaglutide keep people out of the hospital? Not just for cardiac events — for anything.
The study followed 17,604 patients (median age 61, all with established cardiovascular disease and BMI ≥27, none with diabetes) for a median of 3.5 years. There were 11,287 total hospital admissions across the trial. The findings:
Total hospitalizations: 18.3 vs 20.4 admissions per 100 patient-years — a 10% reduction. Days spent in hospital: 157.2 vs 176.2 days per 100 patient-years — an 11% reduction. Hospitalizations for serious adverse events: 15.2 vs 17.1 per 100 patient-years — also an 11% reduction. All statistically significant.
Semaglutide didn’t just reduce heart attacks and strokes. It reduced hospitalizations for any reason. It reduced total days in a hospital bed. There was no heterogeneity across age, sex, or BMI subgroups — the benefit was consistent across the board.
This is not a weight loss drug keeping people thinner. This is a systemic anti-inflammatory, cardioprotective, metabolically optimizing agent that happens to also cause weight loss.
The Longevity Signal Is Everywhere Now
SELECT isn’t the only data point. A separate real-world analysis of over 26,000 patients with heart failure compared GLP-1 receptor agonist users against DPP-4 inhibitor users over five years.
The results made me put my coffee down.
All-cause mortality: 38% reduction. Number needed to treat: 9.1 — meaning for every 9 patients on a GLP-1, one death was prevented. All-cause hospitalization: 29% reduction. Heart failure exacerbation: 17% reduction. And semaglutide specifically showed a 49% mortality reduction.
Forty-nine percent. I called my editor friend Marcus and read him that number. He said, “That can’t be right.” It is. I checked. Twice.
These are numbers that would make front-page news if the drug wasn’t trapped in the “weight loss medication” frame.
And it’s not just cardiovascular. Emerging data shows GLP-1 receptor agonists are associated with reduced risk of Alzheimer’s disease, reduced kidney disease progression, reduced liver fat, and reduced rates of certain cancers. Peter Attia has called them “the most important class of drugs for longevity since statins.” Based on what I’m seeing in the data, that assessment looks increasingly conservative.
Why This Matters More for Women
Heart disease kills more women than all cancers combined.
Let me say that again because it never seems to land: heart disease is the number one cause of death for women in the United States. Not breast cancer. Not lung cancer. Heart disease. My own grandmother died of a heart attack at 67. Everyone in the family was shocked. “But she seemed healthy.” She wasn’t. Nobody checked.
And women are systematically underdiagnosed, undertreated, and underrepresented in cardiovascular research. Women presenting with heart attack symptoms are 50% more likely to be initially misdiagnosed compared to men. They’re less likely to receive guideline-directed therapy. They’re less likely to be referred for cardiac catheterization.
The largest population currently taking these drugs is the same population most underserved by cardiovascular medicine. And the data now shows these drugs provide meaningful cardiovascular protection.
Sit with that for a second.
The women taking semaglutide “for weight loss” may be inadvertently giving themselves the best cardiovascular protection available outside of a statin. The ones who stopped — because they felt guilty, because their insurance dropped coverage, because the cultural narrative told them they were taking the easy way out — may have walked away from a longevity intervention.
That makes me angry. It should make you angry too.
The SELECT hospitalization analysis specifically found no heterogeneity by sex. The benefit for women was the same as for men. In the real-world heart failure study, women actually showed a larger mortality benefit (HR 0.59 vs 0.68). If anything, the signal is stronger for women.
The “Just a Weight Loss Drug” Frame Is Killing People
When insurers classify GLP-1s as “weight management” medications, they can exclude them from formularies. 8.5 million commercially insured Americans have zero GLP-1 coverage for obesity. Medicare — which covers 67 million Americans, the exact population most likely to benefit from cardiovascular protection — doesn’t cover weight loss medications at all.
This isn’t a coverage gap. It’s a mortality gap.
And the people falling into it are disproportionately women, disproportionately older, and disproportionately the people who would benefit most from what this drug actually does.
The framing doesn’t just affect insurance. It affects prescribing behavior — doctors who hesitate to prescribe GLP-1s for patients who “aren’t obese enough” are withholding cardiovascular protection based on an outdated understanding. It affects patient behavior — people who discontinue because they’ve reached their target weight don’t realize they’re also discontinuing cardiovascular protection. It affects public perception — the cultural guilt around GLP-1 use makes patients ashamed of a medication that is, by the data, one of the most beneficial drugs available to them.
The Mechanism Makes Sense
Why would a drug designed to mimic a gut hormone have such broad health benefits? Because GLP-1 receptors aren’t just in your gut. They’re in your heart, your blood vessels, your brain, your kidneys, and your liver.
GLP-1 receptor activation reduces C-reactive protein, TNF-alpha, and IL-6 — markers of systemic inflammation that drive atherosclerosis, neurodegeneration, and cancer progression. The anti-inflammatory effect in SELECT exceeded what weight loss alone would predict. Direct cardiac protection: GLP-1 receptors on cardiomyocytes reduce oxidative stress, inhibit apoptosis, and improve myocardial glucose uptake. Vascular effects improve endothelial function, promote vasodilation, and reduce arterial stiffness. Semaglutide dramatically reduces liver fat, addressing MASLD that affects roughly 25% of the global population. And GLP-1 receptors in the brain appear to reduce amyloid plaque formation and tau phosphorylation — the hallmarks of Alzheimer’s.
This isn’t a weight loss drug with side benefits. This is a multi-system metabolic optimizer that happens to cause weight loss. Framing it as the primary effect is like calling aspirin a “headache drug” and ignoring its cardiovascular protection.
What This Means for Access
If semaglutide is a longevity drug — and the data increasingly says it is — then the access crisis isn’t just about weight loss. It’s about cardiovascular protection, neurological protection, and potentially cancer prevention being locked behind a $900/month price tag.
Let me be blunt: that’s not a pricing decision. That’s a rationing decision. And the people being rationed out are the ones who need it most.
For the millions of people accessing semaglutide through the research peptide market at a fraction of branded pricing, the cost-benefit calculation isn’t even a question. The cardiovascular data alone would justify the expense at branded pricing. At research-grade pricing, with verified purity from a quality vendor, it’s one of the most cost-effective medical interventions available.
I say this not as an endorsement of any specific vendor but as a statement about the data: if you are a woman over 40 with cardiovascular risk factors, and the only thing preventing you from accessing semaglutide is cost, the research peptide market offers a viable path — if you do the vendor due diligence. The molecule doesn’t care what label is on the box.
The Reframe That Needs to Happen
Every conversation about GLP-1 medications that starts with “weight loss” is starting in the wrong place. The question isn’t “do you need to lose weight?” The question is “what is your cardiovascular risk, and would you benefit from a medication that reduces heart attacks, strokes, hospitalizations, and potentially death by double-digit percentages?”
For women — who carry the highest burden of cardiovascular disease while receiving the least cardiovascular attention — this reframe isn’t academic. It’s urgent.
The women taking GLP-1 medications aren’t taking a weight loss drug. They’re taking a cardiovascular drug, an anti-inflammatory drug, a metabolic optimization drug, and a potential neuroprotective agent. The weight loss is real and significant — but it may be the least important thing these medications are doing.
I think about that woman in the cardiologist’s waiting room. I think about her daughter. I hope she didn’t stop taking it. I hope somebody showed her the data instead of the TikTok.
The SELECT trial made the longevity case undeniable. The only question is how long it takes the rest of the system to catch up to the data. Based on my experience covering this industry, I wouldn’t hold my breath — which is why I’m writing about it here instead of waiting for the guidelines committees.